Foghorn Therapeutics Inc. (FHTX)

NASDAQ: FHTX · IEX Real-Time Price · USD

5.90

-0.14 (-2.32%)

Jul 19, 2024, 4:30 PM EDT - Market closed

Foghorn Therapeutics Employees

Foghorn Therapeutics had 116 employees as of December 31, 2023. The number of employees decreased by 45 or -27.95% compared to the previous year.

Employees

116

Change (1Y)

-45

Growth (1Y)

-27.95%

Revenue / Employee

$292,207

Profits / Employee

-$801,328

Market Cap

326.44M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	116	-45	-27.95%
Dec 31, 2022	161	42	35.29%
Dec 31, 2021	119	24	25.26%
Dec 31, 2020	95	-	-

Related Stocks

Company Name	Employees
Zynex	1,100
Spok Holdings	384
Kamada	378
Amarin Corporation	275
ADC Therapeutics	274
Nautilus Biotechnology	167
ALX Oncology Holdings	72
Inozyme Pharma	59

Employee Rankings

FHTX News

7 weeks ago - Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June - GlobeNewsWire
2 months ago - Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline - GlobeNewsWire
2 months ago - Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
2 months ago - Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update - GlobeNewsWire
3 months ago - Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer - GlobeNewsWire
3 months ago - Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs - GlobeNewsWire
3 months ago - Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference - GlobeNewsWire
4 months ago - Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting - GlobeNewsWire